MTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation.

ABSTRACT:

Background

Experimental and preclinical evidence suggest that adoptive transfer of regulatory T (Treg) cells could be an appropriate therapeutic strategy to induce tolerance and improve graft survival in transplanted patients. The University of Kentucky Transplant Service Line is developing a novel phase I/II clinical trial with ex vivo expanded autologous Treg cells as an adoptive cellular therapy in renal transplant recipients who are using everolimus (EVR)-based immunosuppressive regimen.

Methods

The aim of this study was to determine the mechanisms of action and efficacy of EVR for the development of functionally competent Treg cell-based adoptive immunotherapy in transplantation to integrate a common EVR-based regimen in vivo (in the patient) and ex vivo (in the expansi

SUBMITTER: Gedaly R 

PROVIDER: S-EPMC6433536 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature